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S U M M A R Y
Background: Early and accurate risk prediction is an unmet clinical need in patients with infective
endocarditis (IE). The aim of this study was to determine the value of B-type natriuretic peptide (BNP)
levels obtained on admission for the prediction of in-hospital death in IE patients.
Methods: Between 2009 and 2011, consecutive patients with IE diagnosed using the revised Duke
criteria and admitted to the emergency department were evaluated prospectively. BNP levels were
measured on admission. Death during hospitalization was the primary endpoint.
Results: Among 104 consecutive patients with IE and with available BNP levels, 34 (32.7%) died in
hospital. BNP levels were signiﬁcantly higher in patients who died as compared to survivors (709.0 pg/ml
vs. 177.5 pg/ml, p < 0.001). The accuracy of BNP to predict death as quantiﬁed by the area under the
receiver operating characteristics curve was 0.826 (95% conﬁdence interval (CI) 0.747–0.905). The value
of BNP was additive to that provided by clinical, microbiological, and echocardiography assessment. On
multivariate analysis, new heart failure (hazard ratio (HR) 2.02, 95% CI 1.15–3.57, p = 0.015), sepsis (HR
2.10, 95% CI 1.25–3.55, p = 0.005), Staphylococcus aureus endocarditis (HR 2.67, 95% CI 1.60–4.45,
p < 0.001), left ventricular ejection fraction 55% (HR 1.63, 95% CI 1.00–2.65, p = 0.047), and BNP (HR
1.04, 95% CI 1.02–1.06, p < 0.001) were independent predictors of in-hospital mortality.
Conclusion: Among patients with IE, BNP levels obtained on admission provide incremental value for
early and accurate risk prediction.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Despite advances in antimicrobial therapy and the enhanced
ability to diagnose and treat complications, infective endocarditis
(IE) continues to carry a high risk of morbidity and mortality.1–5
The incidence of IE is rising.2–5 IE now represents the fourth leading
cause of life-threatening infectious disease syndromes.1–5 IE is not
a uniform disease, but presents in a variety of different forms,
varying according to the initial clinical manifestations, the
underlying cardiac disease (if any), the microorganism involved,
the presence or absence of complications, and underlying patient* Corresponding author. Tel.: +55 11 26615376; fax: +55 11 26615538.
E-mail address: rinaldo_focaccia@uol.com.br (R.F. Siciliano).
http://dx.doi.org/10.1016/j.ijid.2014.08.017
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).characteristics, and accordingly with substantial differences in in-
hospital mortality rates.2–5 Rapid and accurate identiﬁcation of
patients at highest risk of death may offer the opportunity to
change the course of the disease and improve the prognosis by
referral to a center with on-site cardiac surgery, a more aggressive
treatment strategy (e.g. urgent surgery), and closer follow-up.
Unfortunately, early and accurate risk prediction remains an
unmet clinical need. Accordingly, a simple blood test that would
help predict in-hospital mortality in IE would be highly desirable.
B-type natriuretic peptide (BNP) is a hormone released by
ventricular cardiomyocytes in response to increased myocardial
stretch and volume overload.6 Levels of BNP can be considered
quantitative markers of hemodynamic cardiac stress.7,8 BNP
activation has previously been shown to be a predictor of a worse
outcome in patients with acute coronary syndromes,9,10 stableciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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tation,13,14 aortic stenosis,15 and sepsis.16 The potential role of BNP
in risk prediction in IE has not been well studied.
The aim of this study was to determine the value of BNP levels
obtained on admission for the prediction of in-hospital death in
consecutive IE patients.
2. Methods
2.1. Patients
From July 2009 to January 2011, we prospectively studied
251 consecutive patients who presented to the emergency
department of the Heart Institute (InCor) with suspected IE. The
Heart Institute of the University of Sa˜o Paulo Medical School is a
tertiary cardiology care hospital in Sa˜o Paulo, Brazil. During
hospitalization, 117 patients received a diagnosis of IE based on the
modiﬁed Duke criteria and were included in the study.17 BNP levels
were measured at the discretion of the attending physician.
Patients who did not have BNP levels obtained on admission were
excluded, leaving 104 patients for the ﬁnal analysis (88.9% of all
patients with IE). The local ethics committee approved this study
and waived the need for written informed consent.
The following baseline clinical and laboratory characteristics
were recorded upon patient admission: age, gender, previous
history of heart failure, previous valve dysfunction, hypertension,
diabetes mellitus, chronic renal failure in hemodialysis, nature of
the valve (prosthesis or native), duration of symptoms, embolic
events, sepsis, microorganism, and BNP, creatinine, C-reactive
protein (CRP), and hemoglobin values. New heart failure was
deﬁned as symptoms and signs of heart failure that began together
with other IE symptoms. New valve dysfunction was present if the
patient had had a previous echocardiogram without valve
dysfunction. Sepsis was deﬁned as an infection that included
systemic manifestations of infection.18 At least three pairs of blood
culture samples were obtained. An echocardiogram was performed
in all patients, and the following data were recorded: left
ventricular ejection fraction (LVEF), presence and length of
vegetation, and presence and degree of valvular dysfunction.
The choice between transesophageal and transthoracic echocardi-
ography was based on current IE guidelines.2,19 The presence of a
myocardial abscess was considered based on echocardiography
and surgical ﬁndings. LVEF was calculated according to the
Simpson method, and patients with LVEF above 55% were
considered to have normal systolic function.20
2.2. Measurement of BNP
BNP levels were measured using the Advia Centaur CP
Immunoassay System (Siemens Healthcare Diagnostics, Terry-
town, NY, USA). This assay has a limit of detection of 2 pg/ml, an
upper limit of normal of 5000 pg/ml, and a coefﬁcient of variation
of 5% at 100 pg/ml.
2.3. Clinical follow-up
Patients were followed-up until hospital discharge. The primary
endpoint was in-hospital mortality.
2.4. Statistical analysis
Categorical variables are presented as the frequency and
percentage. Numerical variables are reported as the median and
interquartile range (IQR). The outcome of this study was in-
hospital death. Crude and adjusted relative hazards ratios (HR)
were calculated with a Cox proportional hazards model to identifythe predictors of in-hospital death. BNP was investigated both as a
continuous variable and a categorical variable using the median
BNP value in this cohort as the cut-off level. The adjusted HR was
reported with the corresponding 95% conﬁdence intervals (95% CI).
All clinical variables with a p-value of <0.25 on univariate analysis
were tested in the multivariate model (stepwise forward). We
chose to keep cardiac surgery for all analyses as it could be a strong
predictor of in-hospital mortality and since it could summarize
important unmeasured variables associated with high risk. The
analyses were performed using Stata 11.0 (StataCorp, College
Station, TX, USA) and SPSS version 18 (SPSS Inc., Chicago, IL, USA).
3. Results
The univariate analysis of clinical, echocardiography, laborato-
ry, and follow-up characteristics of the 104 patients with
endocarditis is shown in Table 1. The median age was 53 years,
two-thirds were male, and 44 (42%) had hypertension. Sixty-six
patients (63.5%) were classiﬁed as having deﬁnite IE and 38 (36.5%)
as having possible IE by modiﬁed Duke criteria. At presentation,
33 patients (31.7%) had atrial ﬁbrillation and 37 patients had heart
failure (36.6%; 23.1% had symptoms corresponding to New York
Heart Association (NYHA) IV, 3.8% NYHA III, and 13.7% NYHA II).
Of these latter patients, 23 (62.2%) already had a history of heart
failure before the IE episode.
The most commonly observed microorganisms were viridans
group Streptococcus (37, 35.5%), followed by Staphylococcus aureus
(14, 13.5%), Enterococcus spp (9, 8.6%), coagulase-negative staphy-
lococci (6, 5.7%), and others (13, 12.5%). Culture-negative IE
occurred in 25 (24.0%) patients. Regarding the IE location, 43
(41.3%) were aortic, 51 (49%) mitral, one (0.96%) tricuspid, two
(1.9%) multivalvular, and 10 (10%) were congenital heart disease.
Prosthetic endocarditis occurred in 65 (62.5%) patients. Embolic
events and myocardial abscess diagnosed from admission until
hospital discharge were detected in 14 (13.5%) and nine (8.7%) IE
patients, respectively. Thirty-nine patients (37.5%) required
surgical treatment of endocarditis.
3.1. In-hospital mortality
Overall, 34 patients (32.7%) died in hospital. Causes of death were
heart failure in 28.1% of patients, septic shock in 46.9%, complica-
tions of cardiac surgery in 18.8%, and embolic events in 6.3%.
3.2. BNP levels on admission
BNP levels obtained on admission were signiﬁcantly higher in
patients who died as compared to survivors (median 709.0 pg/ml
(IQR 330.7–1539.0 pg/ml) vs. median 177.5 pg/ml (IQR 85.5–
341.2 pg/ml), p < 0.001; Figure 1). The prognostic accuracy for
in-hospital mortality as quantiﬁed by the area under the receiver
operating characteristics curve was higher for BNP as compared to
CRP (0.826 (95.0% conﬁdence interval (CI) 0.747–0.905) vs. 0.708,
p = 0.08; Figure 2). A BNP cut-off value of 275 pg/ml showed a
sensitivity of 85.3% (95.0% CI 68.9–95.0%), speciﬁcity of 67.1%
(95.0% CI 54.9–77.9%), positive predictive value of 55.8% (95.0% CI
41.3–69.5%), and negative predictive value of 90.4% (95.0% CI
79–96.8%) for in-hospital mortality. Kaplan–Meier analysis using
the median BNP level observed in this cohort as the cut-off value
showed a much higher mortality rate in patients with elevated
BNP levels (>275 pg/ml; p < 0.001), with a very early separation of
the curves (Figure 3). We found a relationship between LVEF
and BNP (median BNP with LVEF 55% 709.0 pg/ml (IQR
295.3–1126.8 pg/ml) vs. BNP with LVEF >55% 217.0 pg/ml (IQR
100.0–464.0 pg/ml); p < 0.001), but not between valvular regurgi-
tation severity and BNP (median BNP with valve dysfunction
Figure 1. Box-plot of B-type natriuretic peptide (BNP) levels in patients discharged
alive (left) and patients who died in hospital (right).
Figure 2. Receiver operating characteristics curve for the accuracy of B-type
natriuretic peptide (BNP) and C-reactive protein (CRP) levels to predict in-hospital
death in patients with infective endocarditis.
Table 1
Univariate analysis of clinical, echocardiography, laboratory, and follow-up characteristics of patients with endocarditisa
Characteristic All patients
(n = 104)
Discharged alive
(n = 70)
In-hospital death
(n = 34)
HR 95% CI p-Value
Baseline characteristics
Age, years, median (IQR) 52.5 (37.3–65.1) 50.5 (35.7–66.5) 60.5 (42.5–64.5) 1.01 0.99–1.02 0.241
Male 68 (65.4%) 43 (61.4%) 25 (73.5%) 1.48 0.77–2.81 0.244
Hypertension 44 (42.3%) 29 (41.4%) 15 (44.1%) 1.08 0.62–1.88 0.795
Diabetes mellitus 10 (9.6%) 3 (4.3%) 7 (20.6%) 2.44 1.45–4.09 0.001
Hemodialysis 4 (3.8%) 1 (1.4%) 3 (8.8%) 2.42 1.28–4.59 0.007
Atrial ﬁbrillation 33 (31.7%) 22 (31.4%) 11 (32.4) 1.03 0.57–1.86 0.924
Symptoms for >7 daysb 62 (62%) 40 (58.0%) 22 (71.0%) 1.50 0.77–2.91 0.234
Sepsis at presentation 44 (42.3%) 25 (35.7%) 19 (55.9%) 1.73 0.99–3.01 0.054
Heart failure at admissionc 37 (36.6%) 17 (37.0%) 20 (58.8%) 2.89 1.59–5.21 <0.001
New heart failureb 27 (27%) 11 (16.2%) 16 (50.0%) 2.70 1.58–4.62 <0.001
Valve dysfunction at admissiond 35 (34%) 21 (30%) 14 (41.2%) 0.93 0.54–1.69 0.899
New valve dysfunctione 17 (19.1%) 10 (16.9%) 7 (23.3%) 1.29 0.66–2.5 0.454
Prosthetic endocarditis 65 (62.5%) 41 (48.6%) 24 (70.6%) 1.44 0.77–2.69 0.253
Aortic IE 43 (41.3%) 29 (41.4%) 14 (41.2%) 0.99 0.57–1.74 0.981
Mitral IE 51 (49.0%) 32 (45.7%) 19 (55.9%) 1.32 0.75–2.30 0.336
Multivalvular IE 2 (1.9%) 1 (1.4%) 1 (2.9%) 1.55 0.37–6.40 0.548
Vegetation 10 mm 23 (22.1%) 9 (12.9%) 14 (41.2%) 2.47 1.49–4.08 <0.001
Myocardial abscess 9 (8.7%) 5 (7.1%) 4 (11.8%) 1.41 0.64–3.11 0.398
LVEF 55%c 22 (21.8%) 9 (12.9%) 13 (41.4%) 2.59 1.52–4.44 0.001
In-hospital course
Embolic event 14 (13.5%) 10 (14.3%) 4 (11.8%) 0.86 0.35–2.07 0.723
Cardiac surgery 39 (37.5%) 27 (38.6%) 12 (35.3%) 0.91 0.51–1.63 0.749
Staphylococcus aureus 14 (13.5%) 3 (4.3%) 11 (32.4%) 3.07 1.96–4.71 <0.001
Laboratory values at admission, median (IQR)
Hemoglobin (g/dl) 11.2 (9.6–13.1) 11.5 (10.1–13.2) 10.0 (9.1–11.1) 0.86 0.74–1.00 0.054
BNP (pg/ml) 275.5 (127.2–735.7) 177.5 (85.5–341.2) 709.0 (330.7–1539.5) 1.05 1.03–1.07 <0.001
CRP (mg/l) 102.5 (53.1–144.2) 93.8 (44.6–121.5) 141.5 (68.5–197.0) 1.06 1.04–1.09 <0.001
Creatinine (mg/dl) 1.1 (0.81–1.5) 0.9 (0.8–1.3) 1.4 (1.0–2.3) 1.17 1.11–1.24 <0.001
HR, hazard ratio; CI, conﬁdence interval; IQR, interquartile range; IE, infective endocarditis; LVEF, left ventricular ejection fraction; BNP, B-type natriuretic peptide; CRP, C-
reactive protein.
a Results are given as the number and percentage unless stated otherwise.
b n = 100.
c n = 101.
d n = 103.
e n = 89.
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dysfunction 231.0 pg/ml (IQR 118.5–580.5 pg/ml); p = 0.277).
3.3. Predictors of in-hospital mortality
The associations of all patient characteristics, in-hospital
course, and in-hospital mortality are shown in Table 1. The
following variables were included in the multivariate model: age,
gender, diabetes, hemodialysis, sepsis at admission, new heartfailure, symptoms >7 days, S. aureus, vegetation 10 mm,
hemoglobin, LVEF 55%, BNP, CRP, creatinine, and cardiac surgery.
The following variables remained statistically signiﬁcant in the
multivariate model: LVEF 55%, new heart failure, S. aureus
endocarditis, BNP, and sepsis (Table 2). We performed another
multivariate model treating BNP as a categorical variable with the
median level observed in this cohort as a threshold (275 pg/ml). In
Figure 3. Kaplan–Meier survival curve of patients presenting with infective
endocarditis to the emergency department according to their level of B-type
natriuretic peptide (BNP).
Table 2
Multivariate analysis for predicting the occurrence of in-hospital mortality, treating
BNP as a continuous variable
Variable Adjusted HR 95% CI P-Value
Staphylococcus aureus endocarditis 2.67 1.60–4.45 <0.001
New heart failure 2.02 1.15–3.57 0.015
BNP (pg/ml) 1.04 1.02–1.06 <0.001
LVEF 55% 1.63 1.00–2.65 0.047
Sepsis 2.10 1.25–3.55 0.005
Cardiac surgery 0.98 0.56–1.73 0.962
BNP, B-type natriuretic peptide; HR, hazard ratio; CI, conﬁdence interval; LVEF, left
ventricular ejection fraction.
Table 3
Multivariate analysis for predicting the occurrence of in-hospital mortality, treating
BNP as a categorical variable
Variable Adjusted HR 95% CI P-Value
Staphylococcus aureus endocarditis 1.99 1.23–3.21 0.005
New heart failure 1.78 1.21–2.80 0.014
BNP 275 pg/ml 4.94 2.06–11.28 <0.001
Diabetes mellitus 1.87 1.25–2.80 0.002
Sepsis 2.25 1.41–3.59 0.001
Vegetation 10 mm 2.14 1.40–3.30 0.001
Cardiac surgery 1.27 0.74–2.19 0.382
BNP, B-type natriuretic peptide; HR, hazard ratio; CI, conﬁdence interval.
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ml, sepsis, diabetes mellitus, and vegetation length 10 mm were
independently related to in-hospital mortality (Table 3).
In a sub-analysis restricted to patients with high BNP levels
(>275 pg/ml), the in-hospital mortality was 50% (8/16 patients) in
those who underwent cardiac surgery versus 58.3% (21/36) in
those who received only antibiotic therapy (p = 0.577). Only ﬁve
patients in the low BNP level group (275 pg/ml) died (four
undergoing cardiac surgery and one in clinical treatment), so a
statistical analysis was not performed in this subgroup.
4. Discussion
In this study of unselected patients presenting with IE to the
emergency department, we evaluated the incremental value of
BNP levels obtained on admission for the prediction of in-hospital
mortality.
Unselected patients with IE continue to have a very high
mortality rate even when treated in tertiary care centers. The in-
hospital mortality in this cohort was substantial (32.7%), reﬂecting
the high-risk case mix (which included patients with congenitalheart disease) and the national referral center status of our
institution. Thus, our study corroborates and extends previous
studies reporting 1-year mortality of approximately 40% and in-
hospital mortality of 20%.4 As previously mentioned, given the
characteristics of our institution, the great majority of patients had
cardiac disease and prosthetic IE with a higher probability of
developing heart failure and potentially higher mortality. On the
other hand, our rate of cardiac surgery was not as high as expected
because in some cases the patient arrived at the emergency
department in a critical clinical condition and died before surgery
could be performed. In contrast to North American and European
registries, this Brazilian IE series showed a lower prevalence of
staphylococcal infection, as reported previously.21,22
Our data corroborate and extend those of previous pilot studies
by showing that BNP levels obtained on admission are signiﬁcantly
higher in patients with IE who die as compared to survivors.23,24
Shiue et al.23 evaluated 45 patients with IE and observed that BNP
levels 400 pg/ml were associated with a 4.1-fold increase in a
composite outcome (i.e., in-hospital mortality, presence of an
annular abscess, and occurrence of a central nervous system event;
63% vs. 15%, p = 0.01). Patients with BNP levels 400 pg/ml were
more likely to have severe aortic and/or mitral valve regurgitation
(p = 0.02), and there was a trend towards reduced left ventricular
systolic function in these patients (p = 0.07). Kahveci et al.
measured N-terminal pro-brain natriuretic peptide (NT-pro-
BNP) levels (Elecsys 2010 Analyzer; Roche Diagnostics GmbH,
Mannheim, Germany) at admission in 45 IE patients, concluding
that NT-pro-BNP was an independent predictor of in-hospital
death or early surgery (HR 1.5, 95% CI 1.2–1.9, p < 0.001). The
authors determined that a cut-off NT-pro-BNP value of 1500 pg/ml
had 97% sensitivity and 92% speciﬁcity for this combined endpoint.
However, in their study, the endpoint was driven mainly by early
surgery (which occurred in 24 of 33 patients) and not mortality.24
The prognostic accuracy of BNP for in-hospital mortality in our
dataset was 0.826, which was higher as compared to that provided
by CRP. This is the ﬁrst study with a sufﬁcient number of deaths to
allow a proper analysis of the incremental value of BNP levels in
the prediction of risk for in-hospital mortality. Conﬁrming the
hypothesis generated in the initial pilot studies, our data showed
BNP levels to provide incremental value on top of all available
clinical, microbiological, and echocardiography information re-
garding the prediction of the risk for in-hospital mortality. BNP was
an independent predictor of mortality if analyzed both as a
continuous variable and as a categorical variable, showing that a
cut-off value of 275 pg/ml had a sensitivity of 85% and speciﬁcity of
67% for in-hospital mortality.
Current guidelines clearly recommend urgent cardiac surgery
in patients with IE who develop symptoms and signs of heart
failure due to severe valvular regurgitation.2,19 Unfortunately, the
clinical diagnosis of heart failure can be challenging, particularly in
patients with comorbidities including systemic infections.7 A
simple and inexpensive biomarker such as BNP could provide
substantial help clinically by complementing clinical assessment
in the individualization of the management of patients with IE. As
the risk associated with cardiac surgery increases with more
advanced forms of clinical heart failure, the early assessment of
BNP as investigated in this study could also improve the timing of
cardiac surgery in IE.
The best BNP level for decisions differs slightly depending upon
the clinical setting. In unselected patients with acute dyspnea who
present to the emergency department, a BNP level of <100 pg/ml
has a high negative predictive value for the presence of heart failure,
and a high positive predictive value if levels are >400 pg/ml.25
In patients with valvular disease, the BNP level also plays a
prognostic role.13,15 Elevated BNP levels independently predict
death or heart failure in patients with organic chronic mitral
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to higher mortality regardless of cardiac function.16,26 Although
septic myocardial dysfunction may be responsible for high BNP
levels in septic patients, preclinical studies have shown that
inﬂammatory cytokines and lipopolysaccharide may have a direct
effect on BNP transcription and translation in cardiomyocytes.27 In
our IE cohort, it is probable that these two mechanisms (presence of
heart failure and inﬂammatory status) were involved with
mortality, since sepsis at admission and staphylococcus IE (indirect
markers of infection severity) had a strong impact on mortality.
The possible clinical application of BNP testing in IE include the
initial triage of patients who require treatment in a hospital with
onsite cardiac surgery, timing of cardiac surgery, and monitoring of
the occurrence of heart failure in IE during the active phase of
disease.13
Our study had some limitations. First, BNP levels were not
available for all patients because our study required the ordering of
BNP assessment by the treating physician (which occurred in
104 out of 117 (90%) consecutive patients with IE). Second, as an
observational study, we could not assess whether the early
detection of high-risk patients using BNP levels could ultimately
contribute to an improvement in outcome. Third, as our study was
performed at a specialist hospital, the utility of BNP assessment in
secondary care hospitals as a triage tool for referral should be
further addressed in future studies.
In conclusion, among consecutive patients with IE, BNP levels
obtained on admission provided incremental value for early and
accurate risk prediction of in-hospital mortality in addition to
clinical, microbiological, and echocardiography information.
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